Rates of Emergence of HIV Drug Resistance in Resource-Limited Settings: A Systematic Review

Joint United Nations Programme on HIV/AIDS. UNAIDS World AIDS Day Report 2011. (Accessed 7 December 2012.) Available from http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/jc2216_worldaidsday_report_2011_en.pdf.

Bendavid E. , Bhattacharya J. The president's emergency plan for AIDS relief in Africa: an evaluation of outcomes. Ann Intern Med 2009; 150: 688–695.

Mtambo A. , Chan K. , Shen A. Treatment limitations imposed by antiretroviral drug resistance mutations: implication for choices of first line regimens in resource-limited settings. HIV Med 2012; 13: 141–147.

Gupta R. , Hill A. , Sawyer A.W. , Pillay D. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008; 47: 712–722.

Cozzi-Lepri A. , Paredes R. , Phillips A. The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI. HIV Med 2012; 13: 62–72.

Bannister W.P. , Cozzi-Lepri A. , Kjaer J. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. J Antimicrob Chemother 2011; 66: 901–911.

von Wyl V. , Yerly S. , Burgisser P. Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. Clin Infect Dis 2009; 48: 979–987.

Truong H.H.M. , Kellogg T.A. , McFarland W. Sentinel surveillance of HIV-1 transmitted drug resistance, acute infection and recent infection. PLoS ONE 2011; 6: e25281.

Taniguchi T. , Nurutdinova D. , Grubb J.R. Transmitted drug-resistant HIV type 1 remains prevalent and impacts virologic outcomes despite genotype-guided antiretroviral therapy. AIDS Res Hum Retroviruses 2012; 28: 259–264.

Buckton A.J. , Prabhu D. , Motamed C. Increased detection of the HIV-1 reverse transcriptase M184V mutation using mutation-specific minority assays in a UK surveillance study suggests evidence of unrecognized transmitted drug resistance. HIV Med 2011; 12: 250–254.

Walensky R.P. , Ciaranello A.L. , Park J.E. , Freedberg K.A. Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature. Clin Infect Dis 2010; 51: 85–92.

D'Aquila R.T. , Johnson V.A. , Welles S.L. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995; 122: 401–408.

Havlir D.V. , Marschner I.C. , Hirsch M.S. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med 1998; 339: 1261–1268.

Miller V. , Phillips A. , Rottmann C. Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure. J Infect Dis 1998; 177: 1521–1532.

Rey D. , Hughes M. , Pi J.T. , Winters M. , Merigan T.C. , Katzenstein D.A. HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17: 203–208.

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264–269.

Bennett D.E. , Camacho R.J. , Otelea D. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 2009; 4: e4724.

Johnson V.A. , Brun-Vezinet F. , Clotet B. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010; 18: 156–163.

Stanford University HIV Drug Resistance Database. (Accessed 12 April 2011.) Available from http://hivdb.stanford.edu/index.html.

Agence Nationale de Recherche sur le SIDA. ANRS HIV-1 genotypic drug resistance interpretation's algorithims. (Updated July 2009. Accessed 12 April 2011.) Available from http://www.hivfrenchresistance.org/archives.html.

Shafer R.W. , Rhee S.Y. , Pillay D. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007; 21: 215–223.

International Treatment Preparedness Coalition. Missing the target #5: improving AIDS drug access and advancing health care for all. (Updated December 2007. Accessed 12 August 2011.) Available from http://aidsdatahub.org/dmdocuments/2007_Improving_AIDS_Drug_Access_and_Advancing_Health_Care_for_All.pdf.pdf.

United Nations. Composition of macro geographical (continental) regions, geographical sub-regions, and selected economic and other groupings. (Updated 2011. Accessed 10 April 2011.) Available from http://millenniumindicators.un.org/unsd/methods/m49/m49regin.htm#africa.

Aghokeng A.F. , Kouanfack C. , Laurent C. Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients. AIDS 2011; 25: 2183–2188.

Price M.A. , Wallis C.L. , Lakhi S. Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses 2011; 27: 5–12.

Monleau M. , Faihun F. , Affolabi D. Antiretroviral drug resistance in HIV-1 infected patients receiving antiretroviral treatment in routine clinics in Cotonou, Benin. Journal of AIDS and HIV Research Vol 2011; 3: 114–120.

Messou E. , Chaix M.L. , Gabillard D. Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire. J Acquir Immune Defic Syndr 2011; 56: 356–364.

Burda S.T. , Viswanath R. , Zhao J. HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naive to HAART in Cameroon. J Med Virol 2010; 82: 187–196.

Kouanfack C. , Montavon C. , Laurent C. Low levels of antiretroviral-resistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment. Clin Infect Dis 2009; 48: 1318–1322.

Muwonga J. , Edidi S. , Butel C. Resistance to antiretroviral drugs in treated and drug-naive patients in the Democratic Republic of Congo. J Acquir Immune Defic Syndr 2011; 57 Suppl 1: S27–S33.

Wang X. , Yang L. , Li H. Factors associated with HIV virologic failure among patients on HAART for one year at three sentinel surveillance sites in China. Curr HIV Res 2011; 9: 103–111.

Dagnra A.Y. , Vidal N. , Mensah A. High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. J Int AIDS Soc 2011; 14: 30.

Soria A. , Porten K. , Fampou-Toundji J.C. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients. Antivir Ther 2009; 14: 339–347.

Hamers R.L. , Wallis C.L. , Kityo C. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011; 11: 750–759.

Sungkanuparph S. , Oyomopito R. , Sirivichayakul S. HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients in Asia: results from the TREAT Asia Studies to Evaluate Resistance-Monitoring Study. Clin Infect Dis 2011; 52: 1053–1057.

Dean J. , Ta Thi T.H. , Dunford L. Prevalence of HIV type 1 antiretroviral drug resistance mutations in Vietnam: a multicenter study. AIDS Res Hum Retroviruses 2011; 27: 797–801.

Liao L. , Xing H. , Shang H. The prevalence of transmitted antiretroviral drug resistance in treatment-naive HIV-infected individuals in China. J Acquir Immune Defic Syndr 2010; 53 Suppl 1: S10–S14.

Yang C. , Nguyen B.D. , Bile E. , Marum L. , Wagar N. , Nkengasong J. Global surveillance of transmitted hiv-1 drug resistance in PEPFAR-supported countries using a broadly sensitive genotyping assay. 18th Conference on Retroviruses and Opportunistic Infections. 27 February–2 March 2011, Boston, MA, USA. Abstract 619.

Ndembi N. , Hamers R. , Sigaloff K. Increasing primary HIV-1 drug resistance among recently infected persons in Uganda, East Africa. 18th Conference on Retroviruses and Opportunistic Infections. 27 February–2 March 2011, Boston, MA, USA. Abstract 621.

Soares C. , Vergara T. , Sucupira M.C. Prevalence of transmitted HIV-1 antiretroviral resistance among patients initiating ART in Brazil: a surveillance using dried blood spots. 18th Conference on Retroviruses and Opportunistic Infections. 27 February–2 March 2011, Boston, MA, USA. Abstract 624.

Vu T. , Le T. , Torok E. HIV-1 drug resistance in antiretroviral-naïve patients with HIV-associated tuberculous meningitis in Ho Chi Minh City, Vietnam. 18th Conference on Retroviruses and Opportunistic Infections. 27 February–2 March 2011, Boston, MA, USA. Abstract 625.

Apisarnthanarak A. , Jirayasethpong T. , Sa-nguansilp C. Antiretroviral drug resistance among antiretroviral-naive persons with recent HIV infection in Thailand. HIV Med 2008; 9: 322–325.

Bussmann H. , de la Hoz Gomez F. , Roels T.H. Prevalence of transmitted HIV drug resistance in Botswana: lessons learned from the HIVDR-Threshold Survey conducted among women presenting for routine antenatal care as part of the 2007 national sentinel survey. AIDS Res Hum Retroviruses 2011; 27: 365–372.

Bansode V. , Drebert Z.J. , Travers S.A. Drug resistance mutations in drug-naive HIV type 1 subtype C-infected individuals from rural Malawi. AIDS Res Hum Retroviruses 2011; 27: 439–444.

Mosha F. , Urassa W. , Aboud S. Prevalence of genotypic resistance to antiretroviral drugs in treatment-naive youths infected with diverse HIV type 1 subtypes and recombinant forms in Dar es Salaam, Tanzania. AIDS Res Hum Retroviruses 2011; 27: 377–382.

Derache A. , Maiga A.I. , Traore O. Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006. J Antimicrob Chemother 2008; 62: 456–463.

Djoko C.F. , Rimoin A.W. , Vidal N. High HIV type 1 group M pol diversity and low rate of antiretroviral resistance mutations among the uniformed services in Kinshasa, Democratic Republic of the Congo. AIDS Res Hum Retroviruses 2011; 27: 323–329.

Carvalho B.C. , Cardoso L.P. , Damasceno S. , Stefani M.M. Moderate prevalence of transmitted drug resistance and interiorization of HIV type 1 subtype C in the inland North State of Tocantins, Brazil. AIDS Res Hum Retroviruses 2011; 27: 1081–1087.

Inocencio L.A. , Pereira A.A. , Sucupira M.C. Brazilian Network for HIV Drug Resistance Surveillance: a survey of individuals recently diagnosed with HIV. J Int AIDS Soc 2009; 12: 20.

Sprinz E. , Netto E.M. , Patelli M. Primary antiretroviral drug resistance among HIV type 1-infected individuals in Brazil. AIDS Res Hum Retroviruses 2009; 25: 861–867.

Yaotsè D.A. , Nicole V. , Roch N.F. , Mireille P.D. , Eric D. , Martine P. Genetic characterization of HIV-1 strains in Togo reveals a high genetic complexity and genotypic drug-resistance mutations in ARV naive patients. Infect Genet Evol 2009; 9: 646–652.

El-Khatib Z. , Katzenstein D. , Marrone G. Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS ONE 2011; 6: e17518.

Fox M.P. , Sanne I.M. , Conradie F. Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/ microl is associated with improved treatment outcomes in South Africa. AIDS 2010; 24: 2041–2050.

Severe P. , Juste M.A. , Ambroise A. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010; 363: 257–265.

Walensky R.P. , Wolf L.L. , Wood R. When to start antiretroviral therapy in resource-limited settings. Ann Intern Med 2009; 151: 157–166.

Obiako O.R. , Murktar H.M. , Ogoina D. Antiretroviral drug resistance–implications for HIV/AIDS reduction in sub-Saharan Africa and other developing countries. Niger J Med 2010; 19: 352–360.

Little S.J. , Frost S.D. , Wong J.K. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 2008; 82: 5510–5518.

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Updated 27 March 2012. Accessed 12 September 2012.) Available from http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.

Thompson M.A. , Aberg J.A. , Hoy J.F. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308: 387–402.

Gill V.S. , Lima V.D. , Zhang W. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis 2010; 50: 98–105.

Murphy R.A. , Sunpath H. , Lu Z. Outcomes after virologic failure of first-line ART in South Africa. AIDS 2010; 24: 1007–1012.

Tuboi S.H. , Pacheco A.G. , Harrison L.H. Mortality associated with discordant responses to antiretroviral therapy in resource-constrained settings. J Acquir Immune Defic Syndr 2010; 53: 70–77.

Kimmel A.D. , Weinstein M.C. , Anglaret X. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr 2010; 54: 258–268.

World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. (Updated 2010. Accessed 2 August 2011.) Available from http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf.

Hong S.Y. , Jonas A. , Dumeni E. Population-based monitoring of HIV drug resistance in Namibia with early warning indicators. J Acquir Immune Defic Syndr 2010; 55: 27–31.

Hirsch M.S. , Gunthard H.F. , Schapiro J.M. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47: 266–285.